DANVERS, Mass., Jan. 9 /PRNewswire-FirstCall/ -- ABIOMED, Inc. , a leading developer, manufacturer and marketer of medical products designed to assist or replace the pumping function of the failing heart, is pleased to announce that Dorothy E. Puhy, who has served as Director of ABIOMED and chair of its Audit Committee since 2003 has been appointed to Lead Director of its Board. As Lead Director, Ms. Puhy will have increased responsibilities with regard to setting strategic goals, working with the Chairman of the Board and organizing sessions with the independent Directors.
Ms. Puhy is currently Executive Vice President, Chief Financial Officer and Assistant Treasurer for the Dana-Farber Cancer Institute. Ms. Puhy has served as the Chief Financial Officer of Dana-Farber since 1994 and has served as its Assistant Treasurer since 1995. From 1985 to 1994, Ms. Puhy held various financial positions at the New England Medical Center Hospitals, Inc., including Chief Financial Officer from 1989 to 1994. Ms. Puhy also served as a Director and chair of the Audit Committee of Reebok International Ltd. Ms. Puhy received her bachelor’s degree from the University of Pennsylvania and her business degree from the Wharton School.
“Dorothy has provided great service to ABIOMED and for that we are very fortunate,” said Michael R. Minogue, Chairman, CEO and President of ABIOMED. “She is well-recognized for her financial expertise and we look forward to continuing to work with her for years to come.”
ABOUT ABIOMED
Based in Danvers, Massachusetts, ABIOMED, Inc. (pronounced “AB'-EE-O-MED”) is a leading developer, manufacturer and marketer of medical products designed to assist or replace the pumping function of the failing heart. ABIOMED currently manufactures and sells the AB5000(TM) Circulatory Support System and the BVS(R) 5000 Biventricular Support System for the temporary support of all patients with failing but potentially recoverable hearts. In Europe, ABIOMED offers the Impella(R) Recover(TM) minimally invasive cardiovascular support systems under CE Mark approval. The Company’s AbioCor(R) Implantable Replacement Heart was the subject of an initial clinical trial under an Investigational Device Exemption from the United States Food and Drug Administration. The AbioCor has not been approved for commercial distribution, and is not available for use or sale outside of the initial clinical trial. For additional information please visit: http://www.abiomed.com.
Contacts: Liza Heapes Investor Relations Contact: ABIOMED, INC. Melody Carey Media Relations Rx Communications Group, LLC 978-646-1668 917-322-2571 mediarelations@abiomed.commcarey@rxir.com FORWARD-LOOKING STATEMENTS
This Release contains forward-looking statements, including statements regarding development of ABIOMED’s existing and new products, the Company’s progress toward commercial growth, and future opportunities. The Company’s actual results may differ materially from those anticipated in these forward- looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing and other risks and challenges detailed in the Company’s filings with the Securities and Exchange Commission, including the Annual Report filed on Form 10-K. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events.
ABIOMED, Inc.
CONTACT: Liza Heapes, Communications Specialist of ABIOMED, INC.,+1-978-646-1668, mediarelations@abiomed.com; or Melody Carey of RxCommunications Group, LLC, +1-917-322-2571, mcarey@rxir.com
Web site: http://www.abiomed.com//
